about
Osteopontin/Eta-1 upregulated in Crohn's disease regulates the Th1 immune responseImbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease.Prevalence of serum celiac antibody in patients with IBD in Japan.T-bet upregulation and subsequent interleukin 12 stimulation are essential for induction of Th1 mediated immunopathology in Crohn's disease.Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease centerUnique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis.Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy.Serum 25-hydroxyvitamin D concentration is inversely associated with mucosal inflammation in patients with ulcerative colitis.Endoscopic and pathologic changes of the upper gastrointestinal tract in Crohn's disease.Management of inflammatory bowel disease: past, present and future.Ulcerative colitis: prevention of relapse.Efficacy and safety of medical therapy for low bone mineral density in patients with inflammatory bowel disease: a meta-analysis and systematic review.Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel disease.Efficacy and Safety of Tacrolimus Therapy for Active Ulcerative Colitis; A Systematic Review and Meta-analysis.Outcome of pregnancy and neonatal complications with anti-tumor necrosis factor-α use in females with immune mediated diseases; a systematic review and meta-analysis.Risk of colorectal cancer in chronic liver diseases: a systematic review and meta-analysis.Meta-analysis of the risk of immune-related adverse events with anti-cytotoxic T-lymphocyte-associated antigen 4 and anti-programmed death 1 therapies.Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-α agents in rheumatic diseases; A systematic review and meta-analysis.Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases.Risk of Colorectal Cancer in Chronic Kidney Disease: A Systematic Review and Meta-Analysis.Risk of Cancer Recurrence Among Individuals Exposed to Antitumor Necrosis Factor Therapy: A Systematic Review and Meta-Analysis of Observational Studies.Age of Diagnosis is Associated with Disease Presentation and Therapeutic Complications in Patients with Crohn's Disease.Risk of Postoperative Complications Among Inflammatory Bowel Disease Patients Treated Preoperatively With Vedolizumab.Parastomal Variceal Bleeding Attributed to Obstructive Pathology Successfully Treated by Percutaneous Variceal Embolization.Two Complex Cases of Hermansky-Pudlak Syndrome Highlight a Potential Biologic Explanation for an Associated Crohn's Disease Phenotype.Novel Topics in Inflammatory Bowel Disease.Lower doses of 6-mercaptopurine/azathioprine bring enough clinical efficacy and therapeutic concentration of erythrocyte 6-mercaptopurine metabolite in Japanese IBD patients.Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease.Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients-authors' reply.Hyperexpression of inducible costimulator and its contribution on lamina propria T cells in inflammatory bowel disease.Pharmacologic therapies for severe steroid refractory hospitalized ulcerative colitis: A network meta-analysis.The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease.Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases - authors' reply.Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study.Preoperative Right-Sided Cardiac Congestion Is Associated with Gastrointestinal Bleeding in Patients with Continuous-Flow Left Ventricular Assist Devices.Approach to Optimize Anti-TNF-α Therapy in Patients With IBD.C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn's disease.The use of infliximab in the prevention of postsurgical recurrence in polysurgery Crohn's disease patients: a pilot open-labeled prospective study.Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy.The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease.
P50
Q28267161-32BC6B27-FE28-440E-BD20-E413C3304EE0Q33300519-B459A27F-0E21-4C15-A60E-6DD625338594Q33605884-55E60DD8-37A4-4C43-B02F-E3C1D50CAEA7Q35596780-EFDB2DEE-3CC3-46B1-8D61-B6B210D0B3C7Q36653732-B06DE634-8B6C-4D7E-B009-B068E5A7CD74Q36667276-909E1D17-B8ED-42EB-BC0F-6C198F292105Q36697972-DDF3532C-8854-4693-8829-172A1120F049Q37034595-F8605D67-0F35-47D9-B48A-5E0564ED1571Q37594593-36A01CD6-5B2F-4C34-8E7A-C7CF0EE15453Q38011223-346D9D84-6308-478A-87CA-9BC4AC8D925DQ38103628-C4D4252A-DBE7-4B4B-9F71-56394B52A2D0Q38131925-A89EB7F9-72AC-498B-9264-EA9529E801F9Q38610083-F47B2EB9-5FD1-407E-9B6D-DF0CAE1355A1Q38662186-B0638E37-122C-4BBB-A17A-303F4B71038EQ39027571-628B96D5-2E2F-490F-A0D5-C13D3CDA975AQ39052028-CC251B96-E7F0-401E-903A-4FD58907936BQ39101223-F6FBC120-61BC-48A8-94ED-E414783C36A4Q39139509-8312ECB3-FC09-4EA6-8D1A-65038E58DA62Q39152159-C004BF07-EABE-40FF-9B8D-D1824968370DQ39445522-AC14FA96-E85C-4EEE-A964-5191509335BCQ39454180-079B372B-0E3C-4D66-8DA7-486371F4C6BDQ39965620-EB8B71C0-7ABD-499D-A24D-59186EAB0348Q40118237-9F0E307B-A752-461E-B235-A56D7551D1BBQ40778265-11E3D17B-5462-47C8-8544-3FBE63E2F5E4Q42329523-D6D07035-9E27-4BCE-AC0A-DE466D0CAFFAQ42661111-90899B92-50D6-4848-8059-A1F0A6C6829FQ42775209-D8E6B2DA-75CD-4B51-AEEE-7044F75DE2CFQ46660990-CB9722EC-4B79-40DD-A477-4BBDE4526852Q47662817-0891EA43-CE5F-4212-85E6-E2ABC75734CCQ48026420-87C04FF3-050D-4E38-94C4-2FE7827F3C11Q48161573-24559B48-0FC9-4959-8DC4-C64779897092Q48194119-49EAFC0E-FAED-4145-8F3A-C231246154EDQ48267381-67C62E24-DB4A-4A43-9457-E2228B07A421Q50054448-303AB035-C34C-4705-830A-B161C31F4E63Q50126190-30810FBD-CFC7-4B38-B6D5-F94B10B633E1Q50713607-4E3C64CC-73C9-435B-A685-83F3FBE8EAC8Q51055322-25A97449-AFDE-4776-82B4-B49B81046DD5Q51369344-BC551A58-87E7-4473-8A64-88BA28A6DCCDQ52673722-897A8082-3348-4629-A4F7-68544E98A973Q52692534-12BE109E-CEAD-415F-9BA1-45B1C8028BBF
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Atsushi Sakuraba
@ast
Atsushi Sakuraba
@en
Atsushi Sakuraba
@es
Atsushi Sakuraba
@nl
Atsushi Sakuraba
@sl
type
label
Atsushi Sakuraba
@ast
Atsushi Sakuraba
@en
Atsushi Sakuraba
@es
Atsushi Sakuraba
@nl
Atsushi Sakuraba
@sl
prefLabel
Atsushi Sakuraba
@ast
Atsushi Sakuraba
@en
Atsushi Sakuraba
@es
Atsushi Sakuraba
@nl
Atsushi Sakuraba
@sl
P106
P1153
6602238908
P31
P496
0000-0003-2519-6129